{
  "Source": "solidot",
  "Title": "癌症疫苗在临床试验中显著改进了总生存率",
  "Link": "https://www.solidot.org/story?sid=76376",
  "Content": "\u003cdiv class=\"p_mainnew\"\u003e\n\t\t\t\t\tUltimovacs 公布了其恶性间皮瘤（Malignant mesothelioma）疫苗 II 期临床试验结果，显示其显著改进了总生存率。恶性间皮瘤是一种高死亡率的恶性癌症，治疗选择很少，一线治疗方法是化疗，二线治疗尚无既定护理标准。Ultimovacs 的疫苗 UV1 是作为二线治疗提供给患者。试验结果显示，UV1 配合 ipilimumab 和 nivolumab 改进了总生存率，死亡风险降低了 27%。\n\u003cp\u003e\u003c/p\u003e\n\u003c!--more--\u003e\n\u003cp\u003e\u003c/p\u003e\n\u003cbr/\u003e\nhttps://ultimovacs.com/investors/news/ultimovacs-announces-nipu-results-presented-at-esmo-2023-significant-and-clinically-meaningful-improvement-in-overall-survival-for-patients-receiving-uv1-cancer-vaccine-in-phase-ii-nipu-trial-in-mali\t\t\t\t\t                \u003c/div\u003e",
  "Date": "2023-10-18T07:36:32Z",
  "Author": "Wilson"
}